Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses RLMD in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named RLMD in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Sergio Traversa | $787,787 | $2,103,545 | — | $4,951,301 | — | — | $1,050,000 | $8,892,633 |
| Chief Executive Officer | ||||||||
| Maged Shenouda | 558,990 | 1,581,644 | — | 3,450,819 | — | — | 500,000 | 6,091,453 |
| Chief Financial Officer | ||||||||
| Charles Ence | 548,990 | 1,119,217 | — | — | — | — | 500,000 | 5,497,026 |
| Chief Accounting and Compliance Officer | ||||||||
| Paul Kelly | 499,800 | 1,085,480 | — | — | — | — | 375,000 | 5,289,099 |
| Chief Operating Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Sergio Traversa | $8,892,633 | — | — | — |
| Maged Shenouda | 6,091,453 | — | — | — |
| Charles Ence | 5,497,026 | — | — | — |
| Paul Kelly | 5,289,099 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Paul Kelly | RSU | 7,316,336 | — | $6,281,367 |
| Sergio Traversa | Option | 192,500 | 3.37 | — |
| Sergio Traversa | Option | 91,941 | 2.48 | — |
| Sergio Traversa | Option | 700,000 | 0.67 | — |
| Maged Shenouda | Option | 41,045 | 2.48 | — |
| Maged Shenouda | Option | 112,500 | 3.37 | — |
| Maged Shenouda | Option | 525,000 | 0.67 | — |
| Maged Shenouda | Option | 828,000 | 4.06 | — |
| Charles Ence | Option | 125,000 | 3.37 | — |
| Charles Ence | Option | 41,045 | 2.48 | — |
| Charles Ence | Option | 350,000 | 0.67 | — |
| Charles Ence | Option | 828,000 | 4.06 | — |
| Paul Kelly | Option | 37,500 | 3.37 | — |
| Paul Kelly | Option | 32,836 | 2.48 | — |
| Paul Kelly | Option | 350,000 | 0.67 | — |
Align executive interests with key growth drivers and stockholder returns; emphasize pay-for-performance; set base salaries, annual cash bonuses, and long-term equity incentive awards around the market median of the peer group.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon Radford |
| Clawback policy | true |
| Anti-hedging | — |
| Anti-pledging | — |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2024 | 2024-05-24 | 7,529,377 | 10,119,590 | 26,154 | 42.66% | Failed |
| 2021 | 2021-05-20 | 10,410,272 | 735,198 | 75,145 | 93.4% | Passed |
| 2018 | 2018-02-02 | 4,250,455 | 248,565 | 38,032 | 94.48% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2024 | 2024-05-24 | 42.66%a |
| 2021 | 2021-05-20 | 93.4%b |
| 2018 | 2018-02-02 | 94.48%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Paul KellyEmployee director | $70,620 | $0 | $0 | — | $802,160 | $872,780 |
| Charles J. CasamentoIndependent · Board Chair · Audit · Corporate Governance and Nominating · Compensation (Chair) · Corporate Governance · Nominating | 182,288 | 0 | 0 | — | 672,003 | 854,291 |
| Fabiana FedeliIndependent · Audit · Corporate Governance and Nominating · Compensation | 116,170 | 0 | 0 | — | 672,003 | 788,173 |
| John GlasspoolIndependent · Audit · Corporate Governance and Nominating · Compensation · Corporate Governance (Chair) · Nominating (Chair) | 111,844 | 0 | 0 | — | 672,003 | 783,847 |
| Sergio TraversaEmployee director | — | — | — | — | — | 0 |
| Maged ShenoudaNot independent · Audit · Compensation · Corporate Governance and Nominating · Departed during FY | — | — | — | — | — | — |
| Charles EnceIndependent | — | — | — | — | — | — |
| Annual cash retainer | $74,152 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 24,717 / 17,919 / 17,919 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $480,922 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $2,818,169 |
| Total cost of the board | $3,299,091 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Relmada Therapeutics | 2025 | Sergio Traversa | $787,787 | — | $4,951,301 | — | $8,892,633 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Sergio Traversa | DEF 14A | 2026-04-17 | 0001213900-26-045192 | Section “Summary Compensation Table” · page 24. As printed: 8,892,633. Filing ↗ |
| 2 | Section 01, Maged Shenouda | DEF 14A | 2026-04-17 | 0001213900-26-045192 | Section “Summary Compensation Table” · page 24. As printed: 6,091,453. Filing ↗ |
| 3 | Section 01, Charles Ence | DEF 14A | 2026-04-17 | 0001213900-26-045192 | Section “Summary Compensation Table” · page 24. As printed: 5,497,026. Filing ↗ |
| 4 | Section 01, Paul Kelly | DEF 14A | 2026-04-17 | 0001213900-26-045192 | Section “Summary Compensation Table” · page 24. As printed: 5,289,099. Filing ↗ |
| 5 | Section 08, Paul Kelly | DEF 14A | 2026-04-17 | 0001213900-26-045192 | Section “Director Compensation”. As printed: 872,780. Filing ↗ |
| 6 | Section 08, Charles J. Casamento | DEF 14A | 2026-04-17 | 0001213900-26-045192 | Section “Director Compensation”. As printed: 854,291. Filing ↗ |
| 7 | Section 08, Fabiana Fedeli | DEF 14A | 2026-04-17 | 0001213900-26-045192 | Section “Director Compensation”. As printed: 788,173. Filing ↗ |
| 8 | Section 08, John Glasspool | DEF 14A | 2026-04-17 | 0001213900-26-045192 | Section “Director Compensation”. As printed: 783,847. Filing ↗ |
| 9 | Section 08, Sergio Traversa | DEF 14A | 2026-04-17 | 0001213900-26-045192 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 10 | Section 08, Maged Shenouda | DEF 14A | 2026-04-17 | 0001213900-26-045192 | Section “Director Compensation”. As printed: —. Filing ↗ |
| 11 | Section 08, Charles Ence | DEF 14A | 2026-04-17 | 0001213900-26-045192 | Section “Director Compensation”. As printed: —. Filing ↗ |
| 12 | Section 06, 2024 vote | Form 8-K | 2024-05-30 | 0001213900-24-047968 | Item 5.07 · say-on-pay result. As reported: 42.66% (votes for as printed: 7,529,377). Filing ↗ |
| 13 | Section 06, 2021 vote | Form 8-K | 2021-05-20 | 0001213900-21-028217 | Item 5.07 · say-on-pay result. As reported: 93.4% (votes for as printed: 10,410,272). Filing ↗ |
| 14 | Section 06, 2018 vote | Form 8-K | 2018-02-05 | 0001213900-18-001309 | Item 5.07 · say-on-pay result. As reported: 94.48% (votes for as printed: 4,250,455). Filing ↗ |
| 15 | Section 09b board cost (computed) | Computed | — | computed | Cash 480,922 + equity 0 + all other 2,818,169 = 3,299,091, summed across the director compensation table rows.machine: formula: Σ = 3,299,091 |
| 16 | Relmada Therapeutics (subject), Section 10b CEO total | DEF 14A | 2026-04-17 | 0001213900-26-045192 | CEO total compensation as printed in Relmada Therapeutics's own proxy. As printed: 8,892,633. Filing ↗ |